Supporting Information

for

Discrete multiporphyrin pseudorotaxane assemblies

from di- and tetravalent porphyrin building blocks

Mirko Lohse¹, Larissa K. S. von Krbek², Sebastian Radunz¹, Suresh Moorthy,²
Christoph A. Schalley*·² and Stefan Hecht*·¹

Address: ¹Department of Chemistry, Humboldt-Universität zu Berlin, Brook-Taylor-Str. 2, 12489 Berlin, Germany. Fax: +49 (0)30 2093-6940; Tel: +49 (0)30 2093-7308
and ²Institut für Chemie und Biochemie, Freie Universität Berlin, Takustraße 3, 14195 Berlin, Germany. Fax: +49(0)308385-5366; Tel: +49(0)308385-2639

Email: Stefan Hecht - sh@chemie.hu-berlin.de; Christoph A. Schalley - christoph@schalley-lab.de

Detailed synthetic procedures

General Methods .................................................................................................................. S2
Synthetic procedures and compound characterization data ............................................... S3
¹H NMR titrations of the pseudorotaxanes........................................................................ S18
Mass spectrometric analysis............................................................................................. S20
References ........................................................................................................................... S23
General methods

Solvents and commercial starting materials were used as supplied. The solvents were dried before use, if necessary, employing an Innovative Technologies solvent purification system (multi-unit micro series). Silica gel for chromatography from Merck (0.035–0.070 mm, 60 Å) was used for column chromatography. The petroleum ether (PE) used had a boiling range of 40–60 °C. NMR spectra were recorded on a 500 MHz (125 MHz for $^{13}$C) Bruker AVANCE II 500 spectrometer or on a 300 MHz (75.6 MHz for $^{13}$C) Bruker DPX 300 spectrometer at 25 °C using the solvent residual proton signals as internal standard ($^1$H: $\delta$(CHCl$_3$) = 7.26 ppm, $\delta$(CH$_2$Cl$_2$) = 5.32 ppm, $\delta$(CH$_3$CN) = 1.94 ppm, $^{13}$C: $\delta$(CHCl$_3$) = 77.16 ppm, $^{13}$C: $\delta$(CH$_2$Cl$_2$) = 53.5 ppm, $^{13}$C: $\delta$(CH$_3$CN) = 118.3 and 1.32 ppm). Ultrahigh-performance liquid chromatography connected to mass spectrometry (UPLC/MS) was performed on a Waters Acquity UPLC equipped with a Waters LCT Premier XE Mass detector for high resolution MS (HRMS, ESI$^+$ ionization) and with Waters Alliance systems (consisting of a Waters Separations Module 2695, a Waters Diode Array Detector 996 and a Waters Mass Detector ZQ 2000). TLC was performed on Merck Silica Gel 60 F254 TLC plates with a fluorescent indicator employing a 254 nm UV lamp for visualization. All procedures linked to photochemistry were performed using spectrophotometric grade solvents.

UV–vis spectroscopy was performed on either a Varian Cary 50 or Varian Cary 60 UV–vis spectrophotometer equipped with a Peltier thermostated cell holder at 25 ± 0.05 °C.

Electrospray ionization reflectron-time-of-flight high resolution mass spectrometric (ESI-ReTOF-HRMS) experiments were conducted on an Agilent 6210 ESI-TOF,
Agilent Technologies, Santa Clara, CA, USA. The flow rate was set to 4 µL/min and the spray voltage to 4 kV. The desolvation gas was set to 1 psi (1 bar). All other parameters were optimized for maximum abundance of the respective [M + H]^+.

Electrospray ionization quadrupole-time-of-flight high resolution mass spectrometric (ESI-Q-TOF-HRMS) experiments were performed with a Synapt G2-S HDMS, Waters Co., Milford, MA, USA. The flow rate was set to 10 µL/min and the spray voltage to 3 kV (1.5 kV for A1_4@C4). The desolvation gas was set to 1 psi (1 bar). All other parameters were optimized for maximum abundance of the respective [M]^+.

Compounds NaBArF [1], C1 [2], 6 [3], 18 [4] were synthesized according to literature.

**Synthetic procedures and compound characterization data**

3-Bromo-5-phenyl-benzaldehyde (3)

The reactant 3,5-dibromobenzaldehyde (6.44 g, 24.40 mmol, 1 equiv) was added to a mixture of phenylboronic acid (2.41 g, 21.96 mmol, 0.9 equiv), Pd(PPh₃)₄ (70 mg, 1.22 mmol, 0.05 equiv), 2 M aqueous Na₂CO₃ solution (20 mL), ethanol (40 mL) and toluene (120 mL). The reaction mixture was stirred at 90–95 °C under a nitrogen atmosphere overnight. After cooling to room temperature the organic layer was separated and the aqueous layer was extracted with Et₂O (3 x 50 mL). The combined
organic phases were dried over MgSO₄ and evaporated to give a crude solid. Purification by column chromatography afforded 5 as a colorless oil (4.787 g, 18.30 mmol, yield 75%). 3,5-Diphenylbenzaldehyde (400 mg) was isolated as the major side-product.

\[ ^1\text{H NMR} \ (500 \text{ MHz, CDCl}_3): \delta = 10.01 \ (s, \text{CHO}), \ 8.01 \ (m, \text{1H}_\text{aryl}), \ 7.96 \ (m, \text{2H}_\text{aryl}), \ 7.59 \ (m, \text{2H}_\text{aryl}), \ 7.49 \ (m, \text{2H}_\text{aryl}), \ 7.43 \ (m, \text{1H}_\text{aryl}) \text{ ppm} \]

\[ ^{13}\text{C NMR} \ (125 \text{ MHz, CDCl}_3): \delta = 190.6, \ 144.0, \ 138.2, \ 138.2, \ 135.6, \ 130.9, \ 129.1, \ 128.6, \ 127.0, \ 126.8, \ 123.7 \text{ ppm.} \]

5,10,15,20-Tetrakis{(3-bromo-5-phenyl)-phenyl}porphyrin (5)

Pyrrole (4, 0.207 mL, 3.00 mmol, 1 equiv), compound 3 (783 mg, 3.00 mmol, 1 equiv) were dissolved in CHCl₃ (400 mL) and 0.6 g molecular sieves (6 Å) were added. The mixture was degassed by bubbling argon through the stirred solution for 15 min after which BF₃·Et₂O (0.040 mL, 0.3 mmol, 0.1 equiv) was added dropwise and stirring was continued for 4 h. Afterwards DDQ (680 mg, 3.0 mmol, 1 equiv) was added and stirring was continued for a further hour, followed by the addition of TEA (2 mL). The major impurities were removed by filtration of the crude reaction mixture through a silica plug with CH₂Cl₂ as the eluting solvent. Pure product 5 was obtained by subsequent column chromatography (SiO₂, petroleum ether/CH₂Cl₂ 7:3) as shimmering violet crystals (270 mg, 0.88 mmol, 29%).

\[ ^1\text{H NMR} \ (500 \text{ MHz, CDCl}_3): \delta = 9.01 \ (s, \text{8H}_\text{aryl}), \ 8.42 \ (m, \text{8H}_\text{aryl}), \ 8.23 \ (t, J = 1.70 \text{ Hz, 4H}_\text{aryl}), \ 7.84 \ (m, \text{8H}_\text{aryl}), \ 7.52 \ (m, \text{8H}, \text{H}_\text{aryl}), \ 7.43 \ (m, \text{4H}_\text{aryl}), \ -2.78 \ (s, \text{2H}, \text{NH}) \]

\[ ^{13}\text{C NMR} \ (125.75 \text{ MHz, CD}_2\text{Cl}_2): \delta = 144.1, \ 141.4,139.4, \ 139.3, \ 135.9, \ 132.2, \ 132.2, \ 129.7, \ 129.1, \ 128.2, \ 127.5, \ 121.6, \ 118.9 \text{ ppm.} \]
Zinc[5,10,15,20-tetrakis{(3-bromo-5-phenyl)phenyl}porphyrin] (1)

Zn(OAc)$_2$ (461 mg, 2.10 mmol, 10 equiv) was added to a stirring solution of 5 (259 mg, 0.21 mmol, 1 equiv) in 30 mL of a chloroform/methanol solvent and the reaction mixture was stirred at room temperature overnight. After removal of the solvents under reduced pressure, the crude product was redissolved in CH$_2$Cl$_2$ and washed with brine. The separated organic layer was dried over MgSO$_4$ and concentrated. Purification by column chromatography (SiO$_2$, petroleum ether/CH$_2$Cl$_2$ 7:3) afforded 1 as violet crystals (270 mg, 2.09 mmol, 99%).

$^1$H NMR (500 MHz, CDCl$_3$): $\delta$ = 9.01 (s, 8H$_{aryl}$), 8.45 (s, 8H, H$_{aryl}$), 8.22 (s, 4H$_{aryl}$), 7.84 (m, 8H$_{aryl}$), 7.47 (m, 8H$_{aryl}$), 7.39 (m, 4H$_{aryl}$) $^{13}$C NMR (125.75 MHz, CDCl$_3$): $\delta$ = 150.1, 144.8, 141.2, 139.4, 135.9, 132.3, 132.1, 129.4, 129.0, 128.1, 127.4, 121.1, 119.8 ppm. ESI-MS: 1298.0 (calc. 1298.0 C$_{68}$H$_{40}$N$_4$Br$_4$Zn).

5,15-Bis{(3-bromo-5-phenyl)phenyl}-10,20-(bismesityl)porphyrin (7)

Molecular sieves (6 Å, 0.06 g) were added to a stirring solution of 5-bromo-[1,1′biphenyl]-3-carbaldehyde (3, 0.227 g, 0.87 mmol, 1 equiv) and 2,2′-(mesitylmethylene)bis(1H-pyrrole) (6, 0.230 g, 0.87 mmol, 1 equiv) in 300 mL of chloroform. The mixture was degassed by bubbling argon through the solution for 20 min before BF$_3$·Et$_2$O (0.03 mL, 0.190 mmol, 0.2 equiv) were added. The reaction mixture was stirred in the dark for 2 h, after which DDQ (0.197 g, 0.87 mmol, 1.0 equiv) was added and the stirring was continued overnight. Afterwards TEA (1 mL) was added and the major impurities were removed by filtration of the crude reaction mixture through a silica plug with CH$_2$Cl$_2$ as the eluting solvent. Pure product 7 was obtained by column chromatography (SiO$_2$, CH$_2$Cl$_2$/petroleum ether 1:3) as a purple solid (0.120 g, 0.24 mmol, 28%).
**1H NMR** (500 MHz, CDCl₃): δ = 8.87 (d, J = 4.8 Hz, 4Hₜₐr), 8.74 (d, J = 4.8 Hz, 4Hₜₐr), 8.45 - 8.32 (m, 4Hₜₐr), 8.18 (s, 4Hₜₐr), 7.87 - 7.75 (m, 4Hₜₐr), 7.45 (m, 8Hₜₐr), 7.28 (m, 4Hₜₐr), 2.62 (s, 6H), 1.85 (s, 12H), 2.64 (s, 2H, NH) **13C NMR** (125.75 MHz, CDCl₃): δ = 144.4, 141.3, 139.5, 139.4, 139.3, 138.2, 137.9, 135.8, 132.0, 129.6, 129.1, 128.2, 127.9, 127.5, 121.5, 118.9, 117.6, 21.7, 21.5 ppm.

**Zinc[5,15-bis{(3-bromo-5-phenyl)phenyl}-10,20-(bismesityl)porphyrin] (2)**

Zinc(II) acetate (0.131 g, 0.60 mmol, 5 equiv) was added to a stirring solution of 7 (0.120 g, 0.12 mmol, 1 equiv) in 20 mL of chloroform/methanol 1:1 and stirred overnight at room temperature. Afterwards the solvent was removed under reduced pressure and the crude product was purified by column chromatography (SiO₂, PE/CH₂Cl₂ 3:1) to obtain 2 as a purple/red solid (0.110 g, 0.10 mmol, 86%).

**1H NMR** (500 MHz, CDCl₃): δ = 8.98 (d, J = 4.6 Hz, 4Hₜₐr), 8.80 (d, J = 4.6 Hz, 4Hₜₐr), 8.52 - 8.32 (m, 4Hₜₐr), 8.20 (t, J = 1.7 Hz, 2Hₜₐr), 7.83 (d, J = 7.5 Hz, 2Hₜₐr), 7.49 (t, J = 7.8 Hz, 2Hₜₐr), 7.41 (m, 4Hₜₐr), 7.30 (s, 4Hₜₐr), 2.62 (s, 6H), 1.82 (s, 12H). **13C NMR** (125.76 MHz, CDCl₃): δ =150.2, 149.8, 145.2, 139.7, 139.3, 138.7, 137.6, 135.8, 132.2, 131.2, 129.1, 128.2, 127.8, 127.5, 120.0, 118.5, 21.7, 21.5 ppm.

**ESI-MS:** 1072.3 (calc. 1072.3 C₆₂H₄₆Br₆N₄Zn)

**Benzyl-(4-bromobenzyl)amine (10)**

Benzyamine (1.158 g, 10.81 mmol, 1 equiv) was added to a solution of 4-bromo- benzaldehyde (9, 2.000 g, 10.81 mmol, 1 equiv) in 15 mL of trimethyl orthoformate and stirred overnight. The solvent was removed under reduced pressure to obtain the
desired product in decent purity which was used without further purification (2.91 g, 10.80 mmol, 98%). NaBH₄ (0.817 g, 21.59 mmol, 2 equiv) were added to an ice-cooled solution of the imine (2.960 g, 10.80 mmol, 1 equiv) in a 1:1 mixture of THF/MeOH (30 mL each). The mixture was allowed to warm to room temperature and stirred for 2 h. The volatiles were removed under reduced pressure and the crude product was dissolved in ethyl acetate. The slurry mixture was filtered through a celite plug using ethyl acetate as the solvent. Pure product 10 was obtained after removal of the solvent under reduced pressure (2.910 g, 10.79 mmol, 98%).

\(^1\)H NMR (500 MHz, CDCl₃): \(\delta = 7.38\) (m, 2H aryl), 7.26 (m, 2H aryl), 7.15 (m, 5H aryl), 3.72 (s, 2H), 3.69 (s, 2H)

\(^{13}\)C NMR (125.75 MHz, CDCl₃): \(\delta = 155.9, 131.7, 128.5, 27.4, 80.3, 28.5\) ppm. ESI-HRMS 276.019 (calc. 276.021 C\(_{14}\)H\(_{15}\)BrN\(^+\))

(tert-Butyloxy carbonyl)(benzyl)4-bromobenzylamine (11)

Triethylamine (2 mL) was added to a stirred solution of 10 (2.688 g, 9.77 mmol, 1 equiv) and (Boc)\(_2\)O (3.271 g, 15.00 mmol, 1.5 equiv) dissolved in 100 mL CH\(_2\)Cl\(_2\). After all of the starting material was consumed (TLC, ca 16 h) the solvent was removed under reduced pressure and excess (Boc)\(_2\)O was removed by bulb-to-bulb distillation. The crude product was purified by column chromatography (SiO\(_2\), petroleum ether/EtOAc 99:1 \(\rightarrow\) 4:1) affording pure 11 as a colorless oil (2.200 g, 5.87 mmol, 60%).

\(^1\)H NMR (500 MHz, CDCl₃): \(\delta = 7.45\) (m 2H aryl), 7.23 (m, 7H aryl), 4.34 (br, 4H), 1.49 (s, 9H) \(^{13}\)C NMR (125.75 MHz, CDCl₃): \(\delta = 140.1, 139.3, 131.5, 129.9, 128.5, 128.2, 127.1, 120.7, 53.1, 52.4\) ppm. ESI-HRMS: 320.056 (calc. 320.040 C\(_{15}\)H\(_{15}\)BrNO\(_2\)\(^+\))
(tert-Butyloxycarbonyl)(benzyl){4-(trimethylsilyl)ethynylbenzyl}amine (12)

Cul (5 mg, 0.03 mmol, 0.1 equiv), triphenylphosphine (35 mg, 0.14 mmol, 0.5 equiv), and 11 (100 mg, 0.27 mmol, 1 equiv) were dissolved in 4 mL of a 1:1 mixture of dry toluene/triethylamine which was degassed by rapid vacuum–argon cycles (5 times). Afterwards, Pd(PPh₃)₄ (31 mg, 0.03 mmol, 0.1 equiv) was added and the solution was degassed again (3 times). After the addition of ethynyltrimethylsilane (0.08 mL, 0.53 mmol, 2 equiv) the solution was stirred at 80 °C for 16 h. When all starting material was consumed (TLC) the mixture was filtered through a plug of celite with ethyl acetate as the eluting solvent. The resulting solution was concentrated under reduced pressure and purified by column chromatography (SiO₂, petroleum ether/EtOAc 15:1 → 9:1) to yield 12 as a colourless solid (0.100 g, 0.26 mmol, 96%).

¹H NMR (500 MHz, CDCl₃): δ = 7.45 (m, 2H aryl), 7.34 (m, 7H aryl), 4.38 (br, 4H), 1.50 (s, 9H), 0.28 (s, 9H)

¹³C NMR (125.75 MHz, CDCl₃): δ = 155.9, 132.1, 128.5, 128.0, 127.8, 127.4, 127.3, 127.1, 104.9, 94.1, 80.2, 49.3, 28.4, 0.4 ppm. ESI-HRMS: 338.158 (calc. 338.157 C₂₀H₂₄NO₂Si⁺)

(tert-Butyloxycarbonyl)(benzyl)4-ethynylbenzylamine (8)

Potassium hydroxide (36 mg, 0.64 mmol, 2.5 equiv) was added to a solution of 12 (100 mg, 0.25 mmol, 1 equiv) in toluene and stirred overnight at room temperature. Afterwards the solvent was removed under reduced pressure and the residue was dissolved in CH₂Cl₂, washed sequentially with 1 M HCl and brine, dried over MgSO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography (SiO₂, petroleum ether:EtOAc 9:1) to give an yellowish oil that solidifies upon standing (65 mg, 0.23 mmol, 90%).

¹H NMR (500 MHz, CDCl₃): δ = 7.51 (m, 2H aryl), 7.33 (m, 7H aryl), 4.42 (br, 4H), 3.17 (s, 1H), 1.51 (s, 9H) ¹³C NMR (125.75 MHz, CDCl₃): δ = 156.1, 132.4, 128.7, 128.2,
128.0, 127.5, 121.1, 80.4, 77.3, 28.6 ppm. **ESI-HRMS**: 338.128 (calc. 338.157

\( \text{C}_{17}\text{H}_{16}\text{NO}_2^+ \))

Boc-protected bisammonium precursor porphyrin (13)

Cul (1.7 mg, 0.01 mmol, 0.2 equiv), triphenylphosphine (2.4 mg, 0.01 mmol, 0.2 equiv), and 2 (50 mg, 0.05 mmol, 1 equiv) were dissolved in 2 mL of dry toluene/triethylamine 1:1 and degassed by rapid vacuum–argon cycles (5 times). Afterwards, Pd(PPh\(_3\))\(_4\) (11 mg, 0.09 mmol, 0.2 equiv) was added and the solution was degassed again (3 times). After the addition of 8 (75 mg, 0.23 mmol, 5 equiv), the solution was stirred at 80 °C for 3 d under a nitrogen atmosphere. When all starting material was consumed (TLC), the mixture was filtered through a plug of celite with CH\(_2\)Cl\(_2\) as the solvent. The resulting solution was concentrated under reduced pressure and purified by column chromatography (SiO\(_2\), CH\(_2\)Cl\(_2\)). The product was precipitated from CH\(_2\)Cl\(_2\)/MeOH by slowly removing CH\(_2\)Cl\(_2\) under vacuum (72 mg, 0.03 mmol, 69%).

\(^1\text{H NMR}\) (600 MHz, CDCl\(_3\)): \(\delta = 9.02\) (m, 4H\(_{\text{aryl}}\)), 3.93 (m, 4H\(_{\text{aryl}}\)), 8.45 (br, 4H\(_{\text{aryl}}\)), 8.25 (s, 2H\(_{\text{aryl}}\)), 7.56 (m, 8H\(_{\text{aryl}}\)), 7.35 (m, 20H\(_{\text{aryl}}\)), 4.20 (br, 8H), 2.66 (s, 6H), 1.89 (s, 12H), 1.32 (br, 18H) \(^{13}\text{C NMR}\) (125.76 MHz, CDCl\(_3\)): \(\delta = 155.7, 145.0, 149.8, 143.9, 140.2, 139.4, 139.3, 139.2, 137.7, 137.3, 135.9, 133.1, 132.1, 131.8, 130.8, 129.2, 128.9,
128.9, 128.0, 127.8, 127.6, 127.5, 127.3, 121.8, 119.2, 118.7, 80.1, 65.7, 28.3, 24.1, 21.7 ppm.

**Target bisammonium porphyrin salt (A2)**

Trifluoroacetic acid (3 mL) was added to a stirring solution of 13 (150 mg, 0.10 mmol, 1 equiv) in CH$_2$Cl$_2$ and the resulting solution was stirred for 3 d. When no starting material was left (TLC), the solvent was removed under reduced pressure until dryness, the residue was dissolved in CH$_2$Cl$_2$ and washed with 1 M NaOH solution. The combined organic phases were dried over MgSO$_4$ and concentrated under reduced pressure to obtain 14 as a purple solid (120 mg, 0.10 mmol, 97%) which was used without further purification.

$^1$H NMR (300 MHz, MeOD): $\delta$ = 9.03 (d, J = 4.9 Hz, 4H$_{aryl}$), 8.83 (d, J = 4.9 Hz, 4H$_{aryl}$), 8.72 (m, 2H$_{aryl}$), 8.61 (m, 2H$_{aryl}$), 8.41 (m, 2H$_{aryl}$), 7.96 (d, J = 7.8 Hz, 4H$_{aryl}$), 7.76 (d, J = 8.2 Hz, 4H$_{aryl}$), 7.50 (m, 28H$_{aryl}$), 4.29 (s, 4H), 4.28 (s, 4H), 2.65 (s, 6H), 1.95 (s, 12H) ppm.

To a solution of 14 (120 mg, 0.10 mmol, 1 equiv) in 20 mL chloroform/methanol 1:1 was added 3 mL of 1 M HCl solution. After stirring for 5 min the solution was concentrated to dryness under reduced pressure to obtain a green solid. This process was repeated three times to fully protonate the compound. The hydrochloride of 14 (100 mg, 0.07 mmol, 1 equiv) was then dissolved in methanol and NaBArF (196 mg, 0.22 mmol, 3.1 equiv) was added. The desired product was precipitated by adding water to the solution and subsequent centrifugation. The obtained sticky solid was dissolved in MeOH, again precipitated with water and centrifuged. This process was repeated three times. A2 was obtained as a purple solid after lyophilisation from benzene (0.160 mg, 0.02 mmol, 58%).
$^1$H NMR (600 MHz, CD$_2$Cl$_2$): $\delta =$ 9.20 (s, 4H$_{aryl}$), 9.01 (s, 4H$_{aryl}$), 8.56 (m, 2H$_{aryl}$), 8.45 (m, 2H$_{aryl}$), 8.34 (s, 2H$_{aryl}$), 7.88 (m, 4H$_{aryl}$), 7.70 (m, 4H$_{aryl}$), 7.66 (m, 24H$_{aryl}$), 7.54 (m, 16H$_{aryl}$), 7.49 (s, 8H$_{aryl}$), 7.33 (m, 12H$_{aryl}$), 4.23 (br, 8H), 2.63 (s, 6H), 1.81 (s, 12H)

$^{13}$C NMR (125.76 MHz, MeOD): $\delta =$163.7, 163.3, 162.4, 135.8, 133.5, 131.3, 131.0, 130.9, 130.6, 130.4, 130.4-130.3, 129.1 - 128.9, 128.5, 126.9, 124.7, 118.5, 52.3, 51.8, 49.9 $^{19}$F NMR (470 MHz, MeOD) -63.85 ppm. ESI-HRMS: 645.317 (calc. 645.313)

Boc-protected tetraammonium precursor porphyrin (15)

Porphyrrin 1 (260 mg, 0.20 mmol, 1.0 equiv), PPh$_3$ (21 mg, 0.08 mmol, 0.4 equiv) and Cul (15 mg, 0.08 mmol, 0.4 equiv) were dissolved in 40 mL toluene/TEA 1:1 and degassed by rapid vacuum–argon cycles (5 times). Afterwards, Pd(PPh$_3$)$_4$ (92 mg, 0.08 mmol, 0.4 equiv) was added and the flask was degassed again (3 times). After 8 (643 mg, 2.00 mmol, 10.0 equiv) was added the solution was stirred at 80 °C for 3 d under a nitrogen atmosphere. Purification was conducted on a short silica plug with CH$_2$Cl$_2$ as the eluent, followed by column chromatography (silica gel, CH$_2$Cl$_2$/MeOH 100:1) and finally precipitated from (MeOH/CH$_2$Cl$_2$) by slowly removing the CH$_2$Cl$_2$ under vacuum to obtain pure 15 (421 mg, 0.19 mmol, 93%) as a purple solid.
**H NMR** (500 MHz, CDCl₃): δ = 9.12 (s, 8Haryl), 8.47 (s, 4Haryl), 8.40 (s, 4Haryl), 8.24 (s, 4Haryl), 7.89 (m, 8Haryl), 7.55 (m, 8Haryl), 7.52 (m, 8Haryl), 7.42 (m, 4Haryl), 7.31 (m, 8Haryl), 7.26 (m, 4Haryl), 7.13 (m, 16Haryl), 4.28 (m, 16H), 1.40 (s, 36H)

**C NMR** (125.76 MHz, CDCl₃): δ = 156.7, 150.3, 143.6, 140.1, 139.6, 137.7, 136.1, 133.4, 132.3, 131.9, 129.4, 129.0, 128.6, 128.0, 127.9, 127.5, 127.3, 122.1, 120.2, 89.7, 80.2, 49.2, 28.3 ppm.

**Target tetraammonium porphyrin salt (A4)**

Precursor 15 (396 mg, 0.18 mmol, 1.0 equiv) was dissolved in 20 mL of CH₂Cl₂ and 6 mL of TFA was added. After stirring overnight at room temperature the reaction mixture was concentrated under reduced pressure. The crude solid was redissolved in CH₂Cl₂ and washed with 2 M aqueous NaHCO₃ solution. The combined organic phases were dried over MgSO₄ and the solvent was removed under reduced pressure to obtain the desired compound 16 (310 mg, 0.18 mmol, 98%) as a purple solid that was used without further purification.

Compound 16 (314 mg, 0.18 mmol, 1.0 equiv) was dissolved in 40 mL of a 1:1 CHCl₃/MeOH mixture and 3 mL 1 M aqueous HCl were added. After 5 min of stirring the volatiles were removed under reduced pressure and this procedure was subsequently repeated another 3 times. The so obtained solid was dried under vacuum overnight. The above hydrochloride of 16 (0.335 g, 0.17 mmol, 1 equiv) was dissolved in 20 mL MeOH and NaBARF (825 mg, 0.93 mmol, 5.5 equiv) was added. After 10 min of stirring, H₂O was added slowly until the precipitation of the desired compound occurs. The precipitate was collected by centrifugation and was then redissolved in MeOH to repeat the precipitation. This procedure was repeated two more times to obtain A4 (703 mg, 0.12 mmol, 68%).
\(^1\)H NMR (500 MHz, CD\(_2\)Cl\(_2\)): \(\delta = 9.30\) (s, 8H aryl), 8.60 (s, 8H aryl), 8.39 (s, 4H aryl), 8.03 (m, 8H aryl), 7.88 (m, 8H aryl), 7.61 (s, 40H aryl), 7.43 (s, 20H aryl), 7.54-7.34 (m, 40H aryl), 4.28 (m, 16H) \(^{13}\)C NMR (126 MHz, MeOD) \(\delta 163.5, 163.1, 162.7, 162.3, 135.8, 133.5, 132.2, 131.3, 131.0, 130.9, 130.6, 130.4, 130.3, 130.1, 129.4, 129.0, 128.5, 126.9, 125.7, 124.7, 122.5, 118.5, 91.4, 90.3, 52.2, 51.7 \(^{19}\)F NMR (470 MHz, MeOD) –64.40 ppm

1,2-Bis(2-(2-bromoethoxy)ethoxy)ethoxy)benzene (19)

\(\text{PPh}_3\) (56.71 g, 261.40 mmol, 6 equiv) followed by \(\text{CBr}_4\) (71.710 g, 261.40 mmol, 6 equiv) were added to a stirring solution of 18 (13.494 g, 36.04 mmol, 1 equiv) in CH\(_2\)Cl\(_2\). The mixture was stirred overnight at room temperature, concentrated under reduced pressure and purified by column chromatography (SiO\(_2\), CH\(_2\)Cl\(_2\)/PE 9:1) to obtain 19 as a yellow oil (10.34 g, 20.54 mmol, 57%).
$^1$H NMR (300 MHz, CDCl$_3$): δ = 6.92 (s, 4H$_{aryl}$), 4.17 (m, 4H), 3.87 (m, 4H), 3.81 (m, 4H), 3.72 (m, 8H), 3.47 (m, 4H)

$^{13}$C NMR (126 MHz, CDCl$_3$) δ = 148.6, 121.3, 114.6, 70.8, 70.4, 70.2, 69.5, 68.6, 30.2 ppm. ESI-HRMS: 499.030 (calc. 499.025 C$_{18}$H$_{26}$O$_6$Br$_2^+$)

3-Formyl-dibenzo[24]crown-8 (20)

3,4-Dihydroxybenzaldehyde (1.381 g, 10.00 mmol, 1 equiv) was dissolved in 100 mL of dry DMF in two necked round-bottomed flask and Cs$_2$CO$_3$ powder (11.40 g, 35.00 mmol, 3.5 equiv) was added. The mixture was allowed to stir for 15 min, after which 19 (5.50 g, 12.66 mmol, 1.1 equiv) dissolved in 100 mL of dry DMF was added dropwise over 2 h at 60 ºC. Then the temperature was raised to 85 ºC and the reaction mixture was stirred for 5 d at this temperature. Afterwards the solvent was removed under reduced pressure, 100 mL of water were added to the residue and the mixture was extracted with CH$_2$Cl$_2$ three times. The combined organic extracts were dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure to give the crude product. Subsequent purification by column chromatography (SiO$_2$, CH$_2$Cl$_2$/MeOH 98:2) yielded 20 (2.1 g, 4.00 mmol, 40%) as a white powder.

$^1$H NMR (300 MHz, CDCl$_3$): δ = 9.79 (s, 1H), 7.40 (dd, J = 8.2, 1.9 Hz, 1H$_{aryl}$), 7.35 (d, J = 1.9 Hz, 1H$_{aryl}$), 6.92 (dd, J = 8.5, 3.5 Hz, 1H$_{aryl}$), 6.88 - 6.81 (m, 4H$_{aryl}$), 4.19 (m, 4H), 4.15 - 4.09 (m, 4H), 3.96 - 3.85 (m, 8H), 3.82 (d, J = 3.8 Hz, 8H)

$^{13}$C NMR (126 MHz, CDCl$_3$) δ = 190.8, 162.4, 154.2, 151.6, 149.0, 148.7, 130.0, 126.7, 121.6, 113.8, 111.8, 110.9, 72.5, 71.4, 71.3, 71.1, 70.3, 69.8, 69.3 ppm. ESI-HRMS: 499.030 (calc. 494.238 C$_{25}$H$_{32}$O$_5$NH$_4^+$)
5,10,15,20-Tetrakis (dibenzo[24]-crown-8)porphyrin (21)

Pyrrole (0.1 mL, 1.50 mmol, 1 equiv) was added to a hot solution (100 °C) of 20 (720 mg, 1.50 mmol, 1 equiv) in 115 mL of propionic acid and the solution was refluxed for 3 h. After removal of the solvent by distillation, the black crude product was purified by column chromatography (neutral alumina, CH₂Cl₂) and preparative GPC to obtain 21 as a purple solid (100 mg, 0.19 mmol, 13%).

¹H NMR (300 MHz, CDCl₃): δ = 9.02 (s, 8H aryl), 7.74 (m, 8H aryl), 7.24 - 7.16 (m, 8H aryl), 6.98 - 6.81 (m, 16H aryl), 4.29 (m, 16H), 4.20 - 3.99 (m, 32H), 3.96 - 3.81 (m, 16H), 3.81 - 3.69 (m, 32H) ¹³C NMR (125.75 MHz, CDCl₃): δ = 172.1, 171.5, 170.1, 149.0, 148.8, 147.0, 153.3, 128.0, 121.5, 120.6, 119.8, 114.16, 111.88, 104.9, 96.9, 82.0, 80.2, 77.3, 71.6, 71.5, 71.4, 70.19, 70.13, 70.08, 70.06, 69.7, 69.6, 69.5, 69.4, 29.8, 14.6, 1.1 ppm

Zinc [5,10,15,20-tetrakis(dibenzo[24]-crown-8)porphyrin] (C4)

Zinc acetate (21 mg, 0.10 mmol, 2 equiv) was added to a stirring solution of 21 (100 mg, 0.05 mmol, 1 equiv) in 20 mL of chloroform/methanol 1:1 and stirred at room temperature overnight. The purple solution was concentrated to dryness and purified by column chromatography (neutral alumina, CH₂Cl₂) to obtain C4 as a purple solid (93 mg, 0.04 mmol, 90%).

¹H NMR (300 MHz, CD₂Cl₂): δ = 9.02 (s, 8H aryl), 7.74 (m, 8H aryl), 7.24 - 7.17 (m, 4H aryl), 6.89 (m, 16H aryl), 4.25 (m, 16H), 4.10 - 3.99 (m, 24H), 3.96 - 3.85 (m, 16H), 3.81 - 3.72 (32, 4H) ¹³C NMR (125.75 MHz, CD₂Cl₂): δ = 150.7, 149.4, 148.9, 147.7, 136.8, 132.3, 128.3, 121.7, 121.1, 114.6, 112.4, 71.3, 70.1, 70.0 ppm. ESI-HRMS: 2179.81 (calc. 2179.80 C₁₁₆H₁₃₂O₃₂N₄ZnNa⁺)
5,15-Bis(dibenzo[24]-crown-8)-10,20-bis(mesityl)porphyrin (22)

Molecular sieves (6 Å, 0.06 g) were added to a stirring solution of 20 (0.903 g, 1.90 mmol, 1 equiv), 2,2’-(mesitylmethylene)bis(1H-pyrrole), and 6 (0.501 g, 1.90 mmol, 1 equiv) in 300 mL chloroform. The mixture was degassed by bubbling argon through the solution for 20 min before BF$_3$·Et$_2$O (0.03 mL, 0.19 mmol, 0.2 equiv) was added and the mixture was stirred in the dark for 3 h at room temperature. Afterwards, DDQ (0.430 g, 1.90 mmol, 1.0 equiv) was added and stirring was continued overnight. Then TEA (1 mL) was added and the major impurities were removed by filtration through a silica plug using CH$_2$Cl$_2$ as eluent. The pure product was obtained by column chromatography (neutral alumina, CH$_2$Cl$_2$/petrolether 1:3) and preparative GPC as a purple solid (0.80 g, 1.12 mmol, 59%).

$^1$H NMR (300 MHz, CD$_2$Cl$_2$): δ = 8.90 (d, J = 4.8 Hz, 4H$_{aryl}$), 8.69 (d, J = 4.8 Hz, 4H$_{aryl}$), 7.83 (d, J = 2.0 Hz, 4H$_{aryl}$), 7.77 (dd, J = 8.1, 2.0 Hz, 2H$_{aryl}$), 7.34 (s, 4H$_{aryl}$), 7.29 (d, J = 8.2 Hz, 2H$_{aryl}$), 7.05 - 6.88 (m, 8H$_{aryl}$), 4.51 - 4.41 (m, 4H), 4.31 (m, 4H), 4.26 - 4.15 (m, 8H), 4.13 - 4.05 (m, 4H), 3.95 (m, 24H), 3.85 (m, 8H), 2.66 (s, 6H), 1.89 - 1.83 (m, 12H) $^{13}$C NMR (125.75 MHz, CDCl$_3$): δ = 149.0, 148.7, 147.5, 139.4, 127.8, 121.5, 114.1, 71.4, 70.0, 69.4, 21.7, 21.4 ppm.
Zinc [5,15-bis(dibenzo[24]-crown-8)-10,20-bis(mesityl)porphyrin] (C2)

Zinc acetate (229 mg, 1.04 mmol, 5 equiv) was added to a stirred solution of 22 (300 mg, 0.21 mmol, 1 equiv) in 20 mL of chloroform/methanol 1:1 and stirred overnight at room temperature. The purple solution was concentrated to dryness under reduced pressure and purified by column chromatography (neutral alumina, CH₂Cl₂) to obtain C2 as a purple solid (298 mg, 0.20 mmol, 95%).

**¹H NMR** (500 MHz, CDCl₃): δ = 8.81 (dd, J = 4.6, 1.8 Hz, 4Haryl), 8.68 (dd, J = 4.6, 2.5 Hz, 4Haryl), 7.69 - 7.60 (m, 4Haryl), 7.20 (s, 4Haryl), 7.06 (dd, J = 7.9, 6.5 Hz, 2Haryl), 6.85 - 6.74 (m, 8Haryl), 4.23 (m, 4H), 4.09 - 4.06 (m, 4H), 4.03 (s, 2H), 4.02 - 3.99 (m, 2H), 3.98 - 3.94 (m, 2H), 3.91 (m, 2H), 3.88 (s, 4H), 3.85 - 3.82 (m, 4H), 3.77 - 3.71 (m, 8H), 3.68 - 3.62 (m, 4H), 3.57 (s, 4H), 3.49 (s, 2H), 3.43 (s, 4H), 2.55 (s, 6H), 1.75 (s, 12H) **¹³C NMR** (126 MHz, CDCl₃) δ = 150.1, 149.8, 148.8, 148.2, 148.1, 146.5, 146.4, 139.2, 137.3, 135.9, 132.3, 130.7, 127.6, 121.3, 119.7, 119.0, 113.9, 71.0, 70.9, 70.7, 70.6, 70.4, 70.3, 69.7, 69.5, 69.4, 69.3, 69.3, 69.2, 69.1, 68.9, 68.8 ppm. **ESI-HRMS**: 1523.573 (calc. 1523.570 C₈₆H₉₂N₄O₁₆ZnNa⁺)
**1H NMR titrations of the pseudorotaxanes**

Figure S1: NMR titration (500 MHz, 298 K, CD₂Cl₂) of C₁ to a 3 mM solution of A₂ showing a slow exchange and signal shifts up to the expected 2:1 ratio.

Figure S2: NMR titration (500 MHz, 298 K, CD₂Cl₂) of C₁ to a 3 mM solution of A₄ showing a slow exchange and signal shifts up to the expected 4:1 ratio.
Figure S3: NMR titration (500 MHz, 298 K, CD$_2$Cl$_2$) of C4 to a 3 mM solution of A1 showing a slow exchange and signal shifts up to the expected 1:4 ratio.

Figure S4: NMR titration (500 MHz, 298 K, CD$_2$Cl$_2$) of C2 to a 3 mM solution of A1 showing a slow exchange and signal shifts up to the expected 1:2 ratio.
Mass spectrometric analysis
[3]- and [5]Pseudorotaxanes with monovalent building blocks A1 or C1

The samples for mass spectrometric analysis of the [3]- and [5]pseudorotaxanes were prepared as follows. Separate solutions of hosts and guests were prepared (CH$_2$Cl$_2$, A1/C1: 4 mM, A2/C2: 2 mM, A4/C4: 1 mM), combined in the respective 1:2, 1:4, 2:1 and 4:1 molar ratios and allowed to equilibrate for 24 hours at room temperature. The solutions of the pseudorotaxanes were diluted to 0.2 µM prior to analysis.

Figure S5: ESI-Q-TOF-MS spectrum of a 2:1 mixture of A1 and C2 (CH$_2$Cl$_2$, 0.2 µM; left hand side) and respective experimental and calculated isotopic patterns of the desired [3]-pseudorotaxane [A1$_2$@C2]$^{2+}$ (m/z 948.4; right hand side).
Figure S6: ESI-Q-TOF-MS spectrum of a 4:1 mixture of A1 and C4 (CH$_2$Cl$_2$, 0.2 µM; left hand side) and respective experimental and calculated isotopic patterns of the desired [5]-pseudorotaxane [A1$_x$@C4]$_2^+$ ($m/z$ 1093.5; right hand side).

[2]- and [3]Pseudorotaxanes with di- and tetravalent building blocks A2, A4, C2 and C4

The samples for mass spectrometric analysis of the multivalent [2]- and [3]pseudorotaxanes were prepared as follows. Separate solutions of hosts and guests were prepared (CH$_2$Cl$_2$, A2/C2: 0.6 mM, A4/C4: 0.3 mM). They were mixed in the respective 1:1, 1:2 and 2:1 molar ratios and allowed to equilibrate for 14 hours at 6 °C. The pseudorotaxane solutions were diluted to 0.2 µM prior to analysis.
Figure S7: ESI-Q-TOF-MS spectrum of a 1:1 mixture of A2 and C2 (CH$_2$Cl$_2$, 0.2 µM; left hand side) and respective experimental and calculated isotopic patterns of the desired [2]pseudorotaxane [A2@C2]$^{2+}$ (m/z 1395.6033 (exp.), 1395.6039 (calc.); right hand side).

Figure S8: ESI-Q-TOF-MS spectrum of a 2:1 mixture of A2 and C4 (CH$_2$Cl$_2$, 0.2 µM; left hand side) and respective experimental and calculated isotopic patterns of the desired [3]-pseudorotaxane [A2$_2$@C4]$^{4+}$ (m/z 1184.5020 (exp.), 1184.5168 (calc.); right hand side).
**Figure S9**: ESI-Q-TOF-MS spectrum of a 1:1 mixture of A4 and C4 (CH$_2$Cl$_2$, 0.2 µM; left hand side) and respective experimental and calculated isotopic patterns of the desired [2]-pseudorotaxane [A4@C4]$^{3+}$ (m/z 988.9071 (exp.), 988.9080 (calc.); right hand side).

**Figure S10**: ESI-Q-TOF-MS spectrum of a 1:2 mixture of A4 and C2 (CH$_2$Cl$_2$, 0.2 µM; left hand side) and respective experimental and calculated isotopic patterns of the desired [3]-pseudorotaxane [A4@C2$_2$]$^{2+}$ (m/z 1199.9935 (exp.), 1199.9951 (calc.); right hand side).

**References**

1. D. L. Reger, T. D. Wright, C. A. Little, J. J. S. Lamba and M. D. Smith, *Inorg. Chem.*, 2001, 40, 3810-3814.

2. C. R. South, M. N. Higley, K. C. F. Leung, D. Lanari, A. Nelson, R. H. Grubbs, J. F. Stoddart and M. Weck, *Chem. Eur. J.*, 2006, 12, 3789-3797.

3. J. Frey, G. Kodis, S. D. Straight, T. A. Moore, A. L. Moore and D. Gust, *J. Phys. Chem. A*, 2012, 117, 607-615.
4. T. Bogaschenko, S. Basok, C. Kulygina, A. Lyapunov and N. Lukyanenko, *Synthesis, 2002*, 2002, 2266-2270.